Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) Debt to Equity (2020 - 2023)

Historic Debt to Equity for Evoke Pharma (EVOK) over the last 4 years, with Q4 2023 value amounting to -$1.94.

  • Evoke Pharma's Debt to Equity fell 25834.81% to -$1.94 in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.94, marking a year-over-year decrease of 25834.81%. This contributed to the annual value of -$1.94 for FY2023, which is 25834.81% down from last year.
  • Latest data reveals that Evoke Pharma reported Debt to Equity of -$1.94 as of Q4 2023, which was down 25834.81% from $5.72 recorded in Q3 2023.
  • Over the past 5 years, Evoke Pharma's Debt to Equity peaked at $5.72 during Q3 2023, and registered a low of -$9.29 during Q2 2023.
  • Its 4-year average for Debt to Equity is -$0.12, with a median of $0.84 in 2021.
  • Within the past 5 years, the most significant YoY rise in Evoke Pharma's Debt to Equity was 53321.77% (2023), while the steepest drop was 143569.04% (2023).
  • Over the past 4 years, Evoke Pharma's Debt to Equity (Quarter) stood at -$1.56 in 2020, then surged by 190.42% to $1.41 in 2021, then dropped by 12.96% to $1.22 in 2022, then plummeted by 258.35% to -$1.94 in 2023.
  • Its Debt to Equity was -$1.94 in Q4 2023, compared to $5.72 in Q3 2023 and -$9.29 in Q2 2023.